On-treatment platelet reactivity: State of the art and perspectives

Vascular Pharmacology

Volumn 77, Issue , 2016, Pages 8-18

  Marcucci, Rossella ^a,b   Grifoni, Elisa ^a,b   Giusti, Betti ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ADENOSINE; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450 2C19; TICLOPIDINE;

ACUTE CORONARY SYNDROME; AGE; BLEEDING; DIABETES MELLITUS; DRUG ELUTING STENT; GENDER; GENETIC POLYMORPHISM; HEART VENTRICLE FUNCTION; HEREDITY; HUMAN; IN-STENT RESTENOSIS; INFLAMMATION; PLATELET REACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; THROMBOCYTE FUNCTION; THROMBOSIS; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GENETICS; HEMORRHAGE; SEX DIFFERENCE; STENT; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ADENOSINE; AGE FACTORS; BLOOD PLATELETS; CYTOCHROME P-450 CYP2C19; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PRASUGREL HYDROCHLORIDE; SEX FACTORS; STENTS; THROMBOSIS; TICLOPIDINE;

EID: 84958042677     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.10.005     Document Type: Review

References (117)

1. Davì G., Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357(24):2482-2494.
2. Eikelboom J.W., Hirsh J., Spencer F.A., Baglin T.P., Weitz J.I. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(Suppl.):e89S-119S.
3. Kaplan Z.S., Jackson S.P. The role of platelets in atherothrombosis. Hematology Am. Soc. Hematol. Educ. Program 2011, 2011:51-61.
4. Fintel D.J. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc. Health Risk. Manag. 2012, 8:77-89.
5. Picker S.M. Platelet function in ischemic heart disease. J. Cardiovasc. Pharmacol. 2013, 61(2):166-174.
6. Marcucci R., Cenci C., Cioni G., Lombardi A., Giusti B., Gensini G.F. Antiplatelets in acute coronary syndrome: personal perspectives. Expert. Rev. Cardiovasc. Ther. 2012, 10(12):1487-1496.
7. Eikelboom J.W., Hirsh J., Spencer F.A., et al. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis (9th edition): American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e89S-e119S.
8. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B., et al. European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur. Heart J. 2004, 25(2):166-181.
9. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345(7):494-502.
10. Yousuf O., Bhatt D.L. The evolution of antiplatelet therapy in cardiovascular disease. Nat. Rev. Cardiol. 2011, 8(10):547-559.
11. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P.G., James S.K., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012, 33(20):2569-2619.
12. Wiviott S.D., Braunwald E., McCabe C.H., TRITON-TIMI 38 Investigators, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2007, 357:2001-2015.
13. Wallentin L., Becker R.C., Budaj A., PLATO Investigators, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 2009, 361:1045-1057.
14. Parodi G., Marcucci R., Valenti R., et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011, 306:1215-1223.
15. Sofi F., Marcucci R., Gori A.M., et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb. Haemost. 2010, 103:841-848.
16. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
17. Aradi D., Komócsi A., Vorobcsuk A., Serebruany V.L. Impact of clopidogrel and potent P2Y 12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb. Haemost. 2013, 109:93-101.
18. Patrono C., Baigent C., Hirsh J., Roth G., American College of Chest Physicians Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl. 6):199S-233S.
19. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(23):2908-2913.
20. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 2005, 45(9):1392-1396.
21. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 2004, 25(21):1903-1910.
22. Gurbel P.A., Tantry U.S. Drug insight: clopidogrel nonresponsiveness. Nat. Clin. Pract. Cardiovasc. Med. 2006, 3(7):387-395.
23. Bonello L., Tantry U.S., Marcucci R., Working Group on High On-Treatment Platelet Reactivity, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 2010, 56(12):919-933.
24. Paniccia R., Antonucci E., Maggini N., et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb. Haemost. 2010, 104(2):287-292.
25. Buonamici P., Marcucci R., Migliorini A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 2007, 49(24):2312-2317.
26. Migliorini A., Valenti R., Marcucci R., et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009, 120(22):2214-2221.
27. Sibbing D., Braun S., Jawansky S., et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Haemost. 2008, 99(1):121-126.
28. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopi- dogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 2008, 29(8):992-1000.
29. Gurbel P.A., Mahla E., Antonino M.J., Tantry U.S. Response variability and the role of platelet function testing. J. Invasive Cardiol. 2009, 21(4):172-178.
30. Aradi D., Komócsi A., Vorobcsuk A., et al. Prognostic significance of high on-clopi- dogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am. Heart J. 2010, 160(3):543-551.
31. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. 2002, 30(11):1288-1295.
32. Savi P., Zachayus J.L., Delesque-Touchard N., Labouret C., Hervé C., Uzabiaga M.F., et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(29):11069-11074.
33. Giusti B., Gori A.M., Marcucci R., Abbate R. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin. Drug Metab. Toxicol. 2010, 6(4):393-407.
34. Giusti B., Gori A.M., Marcucci R., Saracini C., Vestrini A., Abbate R. Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers. Med. 2010, 3:33-50.
35. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N.A., Okazaki O., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 2010, 38(1):92-99.
36. Ding Z., Kim S., Dorsam R.T., Jin J., Kunapuli S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003, 101(10):3908-3914.
37. Marcucci R., Giusti B., Paniccia R., et al. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 2012, 23(8):586-593.
38. Cesari F., Marcucci R., Caporale R., et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb. Haemost. 2008, 99(5):930-935.
39. Marcucci R., Cesari F., Cinotti S., Paniccia R., Gensini G.F., Abbate R., et al. ADAMTS-13 activity in the presence of elevated von Willebrand factor levels as a novel mechanism of residual platelet reactivity in high risk coronary patients on antiplatelet treatment. Thromb. Res. 2008, 123(1):130-136.
40. Fabbri A., Marcucci R., Gori A.M., Giusti B., Paniccia R., Balzi D., Barchielli A., Valente S., Giglioli C., Abbate R., Gensini G.F. A time course study of high on treatment platelet reactivity in acute coronary syndrome patients on dual antiplatelet treatment. Thromb. Res. 2015, 136(3):613-619.
41. Mehta S.R., Tanguay J.F., Eikelboom J.W., CURRENT-OASIS 7 trial investigators, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376(9748):1233-1243.
42. Martin J.F., Bath P.M., Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 1991, 338(8780):1409-1411.
43. Blair T.A., Moore S.F., Hers I. Circulating primers enhance platelet function and induce resistance to antiplatelet therapy. J. Thromb. Haemost. 2015 Aug, 13(8):1479-1493.
44. Smolenski A., Bachmann C., Reinhard K., Hönig-Liedl P., Jarchau T., Hoschuetzky H., et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J. Biol. Chem. 1998, 273:20029-20035.
45. Waldmann R., Nieberding M., Ulrich W. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases. Eur. J. Biochem. 1987, 167:441-448.
46. Aszodi A., Pfeifer A., Ahmad M., Glauner M., Zhou X.H., Ny L., et al. The vasodilatorstimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 1999, 18:37-48.
47. Hurst N.L., Nooney V.B., Raman B., Chirkov Y.Y., De Caterina R., Horowitz J.D. Clopidogrel "resistance": pre- vs post-receptor determinants. Vasc. Pharmacol. 2013, 59:152-161.
48. 2+ responses and platelet aggregation by the P2Y12 receptor antagonists ARC69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 2004, 35:39-46.
49. Cattaneo M., Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J. Thromb. Haemost. 2007, 5:577-582.
50. Iyú D., Glenn J.R., White A.E., Fox S.C., Dovlatova N., Heptinstall S. P2Y12 and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP. Platelets 2011, 22:504-515.
51. Chirkov Y.Y., Chirkova L.P., Horowitz J.D. Suppressed anti-aggregating and cGMPelevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris. Naunyn Schmiedeberg's Arch. Pharmacol. 1996, 354:520-525.
52. Chirkov Y.Y., Holmes A.S., Chirkova L.P., Horowitz J.D. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 1999, 100:129-134.
53. Chirkov Y.Y., Chirkova L.P., Sage R.E., Horowitz J.D. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclic AMPelevating effects of prostaglandin E1. J. Cardiovasc. Pharmacol. 1995, 25:961-966.
54. Nooney V.B., Hurst N.L., Chirkov Y.Y., De Caterina R., Horowitz J.D. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia. Vasc. Pharmacol. 2015, 65-66:17-22.
55. von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., Schömig A. Absorption, metabolization, and antiplatelet effects of 300-600-and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoro- nary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005, 112(19):2946-2950.
56. Montalescot G., Sideris G., Meuleman C., ALBION Trial Investigators, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 2006, 48(5):931-938.
57. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-(Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2005, 111(16):2099-2106.
58. Cuisset T., Frere C., Quilici J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non -ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 2006, 48:1339-1345.
59. Alexopoulos D., Xanthopoulou I., Davlouros P., Plakomyti T.E., Panagiotou A., Mavronasiou E., et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am. Heart J. 2011, 162(4):733-739.
60. Koziński M., Obońska K., Stankowska K., Navarese E.P., Fabiszak T., Stolarek W., et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. Cardiol. J. 2014, 21(5):547-556.
61. Jeong Y.H., Lee S.W., Choi B.R., Kim I.S., Seo M.K., Kwak C.H., et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 2009, 53(13):1101-1109.
62. Gurbel P.A., Bliden K.P., Butler K., Antonino M.J., Wei C., Teng R., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010, 121(10):1188-1199.
63. Hwang S.J., Jeong Y.H., Kim I.S., Park K.S., Kang M.K., Koh J.S., et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2010, 3(5):450-459.
64. Kim I.S., Jeong Y.H., Park Y., Park K.S., Yun S.E., Park J.R., et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. J. Am. Coll. Cardiol. Intv. 2011, 4(4):381-391.
65. Collet J.P., Hulot J.S., Anzaha G., Pena A., Chastre T., Caron C., et al. Montalescot G; CLOVIS-Investigators. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-(Clopidogrel and Response Variability Investigation Study 2). J. Am. Coll. Cardiol. Intv. 2011, 4(4):392-402.
66. Mega J.L., Hochholzer W., Frelinger A.L., Kluk M.J., Angiolillo D.J., Kereiakes D.J., et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011, 306(20):2221-2228.
67. Roberts J.D., Wells G.A., Le May M.R., Labinaz M., Glover C., Froeschl M., et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012, 379(9827):1705-1711.
68. Valgimigli M., Campo G., de Cesare N., Meliga E., Vranckx P., Furgieri A., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009, 119(25):3215-3222.
69. Price M.J., Berger P.B., Teirstein P.S., GRAVITAS Investigators, et al. Standard- vs high- dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
70. Trenk D., Stone G.W., Gawaz M., Kastrati A., Angiolillo D.J., Müller U., et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll. Cardiol. 2012, 59(24):2159-2164.
71. Collet J.P., Cuisset T., Rangé G., ARCTIC Investigators, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N. Engl. J. Med. 2012, 367:2100-2109.
72. Ari H., Ozkan H., Karacinar A., et al. The effect of high-dose clopidogrel treatment in patients with clopidogrel resistance (the EFFICIENT trial). Int. J. Cardiol. 2012, 157(3):374-380.
73. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 2008, 51(14):1404-1411.
74. Bonello L., Camoin-Jau L., Armero S., Com O., Arques S., Burignat-Bonello C., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 2009, 103(1):5-10.
75. Wang X.D., Zhang D.F., Zhuang S.W., Lai Y. Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance. Clin. Cardiol. 2011, 34(5):332-338.
76. Cuisset T., Frere C., Quilici J., Morange P.E., Mouret J.P., Bali L., et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. J. Am. Coll. Cardiol. Intv. 2008, 1(6):649-653.
77. Aradi D., Rideg O., Vorobcsuk A., et al. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur. J. Clin. Investig. 2012, 42(4):384-392.
78. Hazarbasanov D., Velchev V., Finkov B., et al. Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J. Thromb. Thrombolysis 2012, 34(1):85-90.
79. De Caterina R., Marchioli R., Andreotti F. Bedside monitoring of antiplatelet therapy for coronary stenting. N. Engl. J. Med. 2013, 368:871.
80. Capranzano P., Tamburino C., Capodanno D., Miccichè E., D'Urso L., Calvi V., et al. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thromb. Haemost. 2011, 106(6):1149-1157.
81. Aleil B., Jacquemin L., De Poli F., Zaehringer M., Collet J.P., Montalescot G., et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J. Am. Coll. Cardiol. Intv. 2008, 1(6):631-638.
82. Ferreiro J.L., Ueno M., Desai B., Capranzano P., Capodanno D., Angiolillo D.J. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Rev. Esp. Cardiol. (Engl. Ed.) 2012, 65(1):105-106.
83. Trenk D., Hochholzer W., Müller B., Stratz C., Valina C.M., Schmiebusch P., et al. Antiplatelet response to the 150-mg maintenance dose of clopidogrel in patients with insufficient platelet inhibition after clopidogrel loading for elective coronary stent placement. EuroIntervention 2008, 4(2):214-221.
84. Matetzky S., Fefer P., Shenkman B., Varon D., Savion N., Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am. J. Cardiol. 2008, 102(5):524-529.
85. Gurbel P.A., Bliden K.P., Antonino M.J., Stephens G., Gretler D.D., Jurek M.M., et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J. Thromb. Haemost. 2010, 8(1):43-53.
86. Cecchi E., Marcucci R., Chiostri M., Mecarocci V., Spini V., Innocenti L., et al. Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience. Intern. Emerg. Med. 2015, 6.
87. Siller-Matula J.M., Francesconi M., Dechant C., Jilma B., Maurer G., Delle-Karth G., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int. J. Cardiol. 2013, 167(5):2018-2023.
88. Aradi D., Tornyos A., Pintér T., Vorobcsuk A., Kónyi A., Faluközy J., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J. Am. Coll. Cardiol. 2014, 63(11):1061-1070.
89. Neubauer H., Lask S., Engelhardt A., Mügge A. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb. Haemost. 2008, 99(2):357-362.
90. Neubauer H., Kaiser A.F., Endres H.G., Krüger J.C., Engelhardt A., Lask S., et al. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011, 9:3.
91. Mayer K., Schulz S., Bernlochner I., Morath T., Braun S., Hausleiter J., et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb. Haemost. 2014, 112(2):342-351.
92. Aradi D., Komócsi A., Price M.J., Cuisset T., Ari H., Hazarbasanov D., et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int. J. Cardiol. 2013, 167(5):2140-2148.
93. Valenti R., Marcucci R., Comito V., Marrani M., Cantini G., Migliorini A., et al. Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: the REsponsiveness to CLOpidogrel and StEnt Thrombosis (RECLOSE)- 3 Study. J. Am. Coll. Cardiol. Intv. 2015, (submitted for publication).
94. Gori A.M., Marcucci R., Migliorini A., Valenti R., Moschi G., Paniccia R., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol. 2008, 52(9):734-739.
95. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb. Haemost. 2010, 104(2):279-286.
96. Mayer K., Bernlochner I., Braun S., Schulz S., Orban M., Morath T., et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J. Am. Coll. Cardiol. 2014, 64(9):863-871.
97. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
98. Roffi M., Topol E.J. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2004, 25:190-198.
99. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006, 113:1108-1113.
100. Moussa I., Leon M.B., Baim D.S., et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004, 109:2273-2278.
101. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr. Pharm. Des. 2005, 11:2331-2365.
102. DiChiara J., Bliden K.P., Tantry U.S., Hamed M.S., Antonino M.J., Suarez T.A., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007, 56(12):3014-3019.
103. Simpson S.H., Abdelmoneim A.S., Omran D., Featherstone T.R. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am. J. Med. 2014, 127(1). (95.e1-9).
104. Rocca B., Santilli F., Pitocco D., Mucci L., Petrucci G., Vitacolonna E., et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J. Thromb. Haemost. 2012, 10(7):1220-1230.
105. Chhatriwalla A.K., Amin A.P., Kennedy K.F., for the National Cardiovascular Data Registry, et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013, 309:1022-1029.
106. Mehran R., Rao S.V., Bhatt D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011, 123:2736-2747.
107. Ndrepepa G., Berger P.B., Mehilli J., et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J. Am. Coll. Cardiol. 2008, 51:690-697.
108. Sibbing D., Schulz S., Braun S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J. Thromb. Haemost. 2010, 8:250-256.
109. Bonello L., Mancini J., Pansieri M., et al. Relationship between posttreatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J. Thromb. Haemost. 2012, 10:1999-2005.
110. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
111. Cuisset T., Cayla G., Frere C., et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non- ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 2009, 5:325-329.
112. Mokhtar O.A., Lemesle G., Armero S., et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb. Res. 2010, 126:e147-e149.
113. Patti G., Pasceri V., Vizzi V., Ricottini E., Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am. J. Cardiol. 2011, 107:995-1000.
114. Cuisset T., Grosdidier C., Loundou A.D., Quilici J., Loosveld M., Camoin L., et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). J. Am. Coll. Cardiol. Intv. 2013, 6(8):854-863.
115. Tsukahara K., Kimura K., Morita S., et al. Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. Circ. J. 2010, 74:679-685.
116. Parodi G., Bellandi B., Venditti F., et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am. J. Cardiol. 2012, 109:214-218.
117. Aradi D., Kirtane A., Bonello L., Gurbel P.A., Tantry U.S., Huber K., et al. Bleeding and stent thrombosis on P2Y12-inhibitors:collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur. Heart J. 2015, (pii: ehv104).